Papaverine was found to sensitize tumors in a way that could potentially improve their response to radiation therapy in patients with certain tumor types.
In mice, DNA-encoded plasmids generated sufficient in vivo expression of immune checkpoint antibody CTLA-4; DMabs may one day rival traditional mAbs.
Researchers proposed lowering the circulating plasma cell threshold from 20% to 5% for plasma cell leukemia, thus creating a new definition for diagnosis.
A new screening approach identifies more than 200 lncRNAs essential for survival in CML cells, suggesting lncRNAs could be good prospective targets for therapies.
Evidence is building to show that most people have preexisting immunity to CRISPR-based therapies. In cancer, however, it's unclear how much that matters.
Researchers are learning that roughly half of survivors live with a moderate to high degree of fear of recurrence, and teaching techniques to better cope with uncertainty is one way to help.
Lower doses and shorter treatment regimens have the potential to reduce both physical and financial toxicity for patients.
"CD19 CAR therapy has paved the way for a new field of medicine based on the genetic instruction of T-cell responses," according to Dr Michel Sadelin.
Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
XPO1 inhibition restores the ability of intranuclear tumor suppressor genes to disrupt oncoproteins; it is emerging as a promising new investigational strategy in MM.
Panobinostat plus bicalutamide increased radiographic progression-free survival in patients with CRPC resistant to second-line antiandrogen therapy.
Dacarbazine, although once a staple of melanoma therapy, essentially has no current role in the treatment of any type or stage of melanoma.
EUTOS long-term survival score better predicted prognosis for those with chronic myeloid leukemia who had been treated with TKIs—especially among elderly patients.
The findings may support the triplet regimen as a new standard of care for these patients, according to Dr Facon.
Interferon or high-dose interleukin-2 were the only available options for the treatment of metastatic RCC until 2005.
Researchers also used the trial to collect more information on safety, patient‐reported outcomes, and a specific premedication treatment protocol.
Trade-offs should be carefully considered, as data have indicated that many QoL factors eventually even out.
Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
High-risk early breast cancer patients with circulating tumor cells 2 years after chemotherapy had greater risk of recurrence. Possible interventions are needed.
Evidence is growing to support the idea that immune checkpoint inhibitors can speed up tumor growth, although the exact mechanism of how this occurs is still unclear.
Among 4 specific breast cancer stages, T2N1 cancers showed the highest risk for local recurrence, regional recurrence, and distant metastases within 10 years from diagnosis.
Trials, Collaboration Might Help Reduce Survival Disparities Between Community, Academic Cancer Centers
Better collaboration between community and academic cancer centers could benefit patients.
The model was developed using machine learning techniques and programmed with data from a Danish cancer registry.
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
The majority of patients studied who stopped TKI therapy remained treatment-free at 3 years.
In the immunotherapy era, the optimal setting and sequencing of BRAF+MEK inhibition remains unresolved.
Genomic and proteomic studies of medulloblastoma samples helped researchers characterize new cancer subtypes and targets.
Dr Vorobiof discusses the important patient factors that can be missed via standard data collection methods for those with cancer.
Image-guided microwave ablation of early-stage renal tumors shows promise but a new retrospective study from the Mayo Clinic found some cases of major bleeding.
Immune checkpoint inhibitor pneumonitis is a potentially serious complication that may occur more in patients with lung cancer than previously suspected.
Cost-effectiveness of TKIs for CML treatment is a complex topic that requires consideration of multiple factors — not just apparent costs to payers.
Tackling EBV-Associated Lymphoma: Early Research Finds Overall Survival Benefit After Donor Transplants
Use of experimental T cells that target Epstein-Barr virus proteins in relapsed or refractory lymphoma may improve overall survival.
A draft guideline from the National Consensus Project for Quality Palliative Care describes best practices for caring for individuals who are seriously ill.
Utilizing data from the PREVAIL dataset, researchers developed mathematical models that can provide prognostic information for men being treated with enzalutamide for chemotherapy-naïve metastatic castration-resistant prostate cancer.
Omega-3 fatty acids found in fish oil act through a host receptor, GPR120, to confer anti-prostate cancer effects. Additional studies are underway.
A change in diagnosis was often the result of review by a multidisciplinary tumor board at the NCI-designated cancer center.
A small study identified risk factors for SPM, but survival benefits of treatment were still determined to outweigh risk.
Younger Women May Have Better Chance at Ovarian Function Recovery After Treatment for Hodgkin Lymphoma
Women aged 35 years or older diagnosed with Hodgkin lymphoma should discuss fertility preservation prior to treatment.
A high prevalence of patients with renal cell carcinoma reported distress, highlighting the need for better psychosocial screening of patients.
Researchers compared the immune microenvironments of primary tumors with those at sites of metastases.
Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.
Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.
This in-depth review examines the inherent challenges of providing cancer care for incarcerated patients.
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Findings from the SPARTAN trial show that HRQoL is not diminished by adding apalutamide to androgen deprivation therapy in men with asymptomatic, nonmetastatic CRPC.
The Leukemia & Lymphoma Society partnered with Sutro Biopharma to test the safety of the investigational CD74-targeting antibody-drug conjugate STRO-001 for 2 blood cancers.
A matching-adjusted indirect comparison concluded that ponatinib offers better disease control compared with bosutinib in certain patients.
Oropharyngeal cancers have become the most common HPV-associated malignancies in the US, where the rate of vaccination against HPV lags compared with other countries.
Stool burden can be a particularly challenging aspect of colonoscopies, making potentially cancerous lesions easier to miss.
A patient's frailty has been determined to be associated with a higher likelihood of developing toxicities, a poor therapeutic response, and decreased survival.
Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.
With newer treatments, alternatives to dasatinib exist, if needed.
Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.
Targeted treatment options for patients with relapsed/refractory multiple myeloma are described.
Humans are used to seeing canines used as tools in forensics — their skills are often harnessed to smell out drugs or trail a criminal. Some dogs are even used to locate household pests. The use of canines to detect lung cancer from smell alone, however, is a new prospect for oncologists and their patients.
Updated results show prolonged responses to brain metastases.
Researchers found that doubling in KIM-1 plasma concentrations was associated with an increased risk of developing RCC and poorer survival.
Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
The VEGFR/EGFR inhibitor anlotinib prolonged PFS and OS in Chinese patients with NSCLC, but additional studies are needed to determine its benefit in other populations.
Oral treatment with talazoparib improved progression-free survival and some quality of life measures compared with standard chemotherapy.
Double mutants may predict resistance to PARP inhibitors and could also indicate sensitivity to alternative treatments.
"Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
A preplanned exploratory analysis in a subset of patients from the phase 3 FLAURA study with CNS metastases at baseline shows "impressive" clinical activity in the CNS.
A new white paper emphasizes the benefits of germline testing.
Research is still needed to explore the association between cancer chemotherapeutics and rheumatoid arthritis.
A new model has the potential to identify patients with melanoma who could benefit from treatment with checkpoint inhibitors.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
Progressive telomere shortening during successive cell divisions is thought to contribute to phase transition in chronic myeloid leukemia.
Genomics could guide the decision about whether a patient should undergo implant reconstruction or autologous tissue-based reconstruction.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
The likelihood of a patient with breast cancer receiving genetic analysis more than doubled if she went to a surgeon with a high propensity for ordering such tests.
Circulating tumor DNA levels measured as early as 3 weeks post-therapy may provide clues about long-term outcomes in this lymphoma subtype.
A meta-analysis compared outcomes between the use of partial nephrectomy using a robotic surgical approach and open or laparoscopic partial nephrectomy.
Although checkpoint inhibitors are active against melanoma-linked brain metastases, researchers are interested in exploring combination approaches.
Metabolites from the Krebs cycle were found to suppress the DNA-repair pathway required for the preservation of genomic integrity.
Researchers Use Artificial Intelligence to Predict Patient Survival from Pathology Images in Lung Cancer
Artificial intelligence techniques are being employed to build complex new multivariate prognostic models for patients with lung cancer and other malignancies.
Many patients with follicular lymphoma will be asymptomatic and present with variable cervical, axillary, and inguinal adenopathy.
Having a high body mass index reduces the risk for developing breast cancer before menopause, but more research is needed to understand the biological mechanism.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
Early preclinical and clinical data have shown that selinexor has broad activity against multiple hematologic malignancies and notable antimyeloma activity.
Researchers are promoting physician and patient awareness about the potential tie between depression and certain therapies.
Any images and personal stories that remind people about skin cancer, what to look for, even scars after surgery, really help save lives.
Even after an adverse event due to treatment with a checkpoint inhibitor, some patients may benefit from re-treatment with drugs from this class.
A growing body of evidence points to infiltrating myeloid-derived suppressor cells as key players in tumor progression and acquired treatment resistance.
Studies attempting to link ASA to a reduction in the risk of CRC have had mixed results.
Tumor cell lines derived from single cells and curated at different reference labs have quietly evolved in vitro, accumulating distinct genomic aberrations.
The development of BRCA-targeted therapies might offer the best opportunities to bring pancreatic cancer into the precision-oncology era.
A review published in Blood highlights new approaches that are being investigated to treat PCNSL based on the mutational landscape and signaling pathways that are extant in the disease.
Perspectives differ on whether ponatinib is a niche drug that should be reserved for younger patients.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
New-onset adult diabetes mellitus appears to be both a risk factor for and a sequelae of pancreatic cancer.
The vitamin D response element plays a direct role in regulating gene expression, a potential mechanism to explain how vitamin D is involved with malignancy.
Any new study of pazopanib or sunitinib must be placed in perspective of the changing treatment landscape and the market entrance of new immunotherapies.
Using Autologous Tumor-Infiltrating Lymphocytes to Mediate Tumor Regression: Promising Outcomes in Experimental Research
Experimental research may provide a blue print for the treatment of many types of cancer.
A meta-analysis of 20 randomized clinical trials found that men may infer a greater benefit from immune checkpoint inhibition.
The breakdown of the medication abiraterone, which can be accelerated by the presence of a specific gene variant, produces drug metabolites that are suspected to play a role in the progression of prostate cancer to castration-resistant forms of disease.
The identification of driver mutations in myelofibrosis has helped cement understanding of the pathophysiology of the disease and has kick-started the development of targeted therapies.
The IASLC released guidance on the use of biopsies for the detection of EGFR and other tumor mutations in patients with NSCLC.
A large, long-term study found a 97% event-free survival rate at 18 months.
Two recent studies have found that signaling from other ERBB family members is necessary for survival and proliferation in KRAS-driven tumors, and that afatinib and neratinib produce an antitumor response.
Selecting therapies for patients with multiple myeloma is challenging because the disease is inherently heterogeneous.
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
Next-Generation Sequencing Adds Value by Detecting More Mutations Than Polymerase Chain Reaction in Melanoma
Since next-generation sequencing reflex testing has been implemented at Case Western Reserve University School of Medicine, several cases of potentially actionable mutations have been identified that would not have been caught by PCR alone.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Evidence Grows Linking BIA-ALCL to Textured Surface of Some Breast Implants
- Could Cytostatic Drugs Unleash Antitumor Immunity in Lung Cancer?
- Primary End Point Not Met in Trial Testing Nivolumab Monotherapy for DLBCL
- Increased Risk of Myeloma in African Americans Driven By Higher Rates of 3 Disease Subtypes
- Fermented Dairy and Cancer
- In Mice, Lithium Shown to Reverse Dysfunction Related to Brain Tumor Compression
- Fermented Dairy and Cancer
- Immunotherapy Plus Chemotherapy May Turn Cold Tumors Hot
- Spending on Medical DTC Advertising Increased Dramatically Over the Past 20 Years
- SURTIME Trial: Surgery May Not Be Most Appropriate Frontline Treatment in mRCC